MK-2214

Contents

• What is MK-2214?
• How does MK-2214 work?
• Which conditions is MK-2214 studied for?
• How is MK-2214 given?
• What do the clinical trials show?
• What side effects are known?

What is MK-2214?

MK-2214 is an investigational protein-based substance being developed for Alzheimer's disease. It is classified under nervous system diseases in the trial registry and is supplied by Merck & Co. Inc.^[1] The substance has no marketing authorisation in the product records, meaning it is not yet an approved medicine.^[1] MK-2214 is being studied as a potential treatment designed to slow down Alzheimer's disease.^[2]

How does MK-2214 work?

The study treatment is designed to slow the spread of tau in the brain. Tau is a protein that accumulates in Alzheimer's disease and damages brain cells.^[2] The trial measures whether MK-2214 can slow this tau spreading compared to a placebo, using tau positron emission tomography (PET) imaging.^[1] The exact molecular target of MK-2214 is not described in the available sources.

Which conditions is MK-2214 studied for?

• Early Alzheimer's disease — a type of dementia that causes loss of memory, communication and decision-making skills, and can limit a person's ability to do daily tasks.^[2]

How is MK-2214 given?

MK-2214 is given as a solution for injection or infusion, administered by intravenous infusion.^[1] The trial also uses a placebo to MK-2214 as a comparison arm.^[1] The dose of MK-2214 was not reported in the trial registry, so it is not stated here.^[1]

What do the clinical trials show?

There is one registered clinical trial of MK-2214, a Phase 2 study in people with early Alzheimer's disease.^[1] The trial is authorised but not yet recruiting.^[1] It plans to enrol 341 participants aged 50 to 85 years.^[1][2]

The trial compares MK-2214 against a placebo. Participants will receive either MK-2214 or placebo by intravenous infusion.^[1] The study also uses florquinitau F18, a radioactive tracer given by intravenous injection for tau PET imaging.^[1]

The main outcomes measured are the change from baseline in tau PET standardized uptake value ratio (SUVr), the number of participants who experience one or more adverse events, and the number who discontinue study intervention due to an adverse event.^[1] The tau PET SUVr shows how much tau has built up in the brain over time.

What side effects are known?

The available sources do not report specific side effects of MK-2214. The trial is designed to evaluate safety and tolerability, including the number of participants who experience adverse events.^[1] No further information on side effects is provided in the sources.